News &amp; Updates

The combination of stereotactic radiosurgery (SRS) with targeted chemotherapy treatments appears to improve disease outcomes in cancer patients with brain metastasis, reports a recent study.

Add-on targeted therapies boost stereotactic radiosurgery efficacy in brain metastasis

Older men of lower socioeconomic status less likely to receive specialized palliative care

Older patients, men, and those belonging to lower socioeconomic groups tend to receive less hospital-based specialized palliative care (SPC), reports a recent study. Such a pattern indicates potential under-treatment in these populations.

Older men of lower socioeconomic status less likely to receive specialized palliative care

Relugolix leads to rapid, sustained profound testosterone suppression in advanced PCa

25 Aug 2022 by

Use of the oral non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix led to faster and greater sustained profound testosterone suppression than leuprolide in men with advanced prostate cancer, according to results of the phase III HERO study presented at EAU 2022.

Relugolix leads to rapid, sustained profound testosterone suppression in advanced PCa

25 Aug 2022

Lymph node ratio predicts survival in HPV+ oropharyngeal cancer

In patients with HPV-positive oropharyngeal cancer, lymph node ratio may be a better predictor of survival and metastasis than lymph node number, reports a recent study.

Lymph node ratio predicts survival in HPV+ oropharyngeal cancer

Persistent microscopic hematuria not a risk factor for early-onset urothelial, renal cell carcinoma

The presence of persistent isolated microscopic blood in urine does not appear to convey an increased risk of early-onset urothelial or renal cell carcinoma among adolescents, a study has found.

Persistent microscopic hematuria not a risk factor for early-onset urothelial, renal cell carcinoma

Low fixed-dose rasburicase achieves target UA levels in treatment of tumour lysis syndrome

24 Aug 2022

Treatment with rasburicase at low fixed dose is effective in adults with tumour lysis syndrome, results of a study have shown.

Low fixed-dose rasburicase achieves target UA levels in treatment of tumour lysis syndrome

24 Aug 2022

FLT3 inhibitor improves survival in patients with FLT3+ acute myeloid leukaemia

Patients diagnosed with acute myeloid leukaemia with an FLT3 mutation (FLT3+ AML) may benefit from the addition of an FLT3 inhibitor to intensive chemotherapy postinduction by improving event-free (EFS) or overall survival (OS), suggests a study.

FLT3 inhibitor improves survival in patients with FLT3+ acute myeloid leukaemia

23 Aug 2022

Overexpression of a long noncoding RNA tied to worse cancer prognosis

The overexpression of the hepatocellular carcinoma upregulated EZH2-associated family of long noncoding RNA appears to be a risk factor for worse clinicopathologic characteristics and outcomes for cancer patients, reports a recent meta-analysis.

Overexpression of a long noncoding RNA tied to worse cancer prognosis

First-line tislelizumab + chemo improves OS in advanced/metastatic ESCC

23 Aug 2022 by

First-line treatment with tislelizumab + chemotherapy significantly improves overall survival (OS) in patients with advanced or metastatic oesophageal squamous cell carcinoma (ESCC) compared with chemotherapy alone, according to an interim analysis of the RATIONALE-306* trial presented at ESMO GI 2022.

First-line tislelizumab + chemo improves OS in advanced/metastatic ESCC